Journal article

Viral vectors as vaccine platforms: from immunogenicity to impact

Abstract:: Viral vectors are the vaccine platform of choice for many pathogens that have thwarted efforts towards control using conventional vaccine approaches. Although the STEP trial encumbered development of recombinant human adenovirus vectors only a few years ago, replication-deficient simian adenoviruses have since emerged as a crucial component of clinically effective prime-boost regimens. The vectors discussed here elicit functionally relevant cellular and humoral immune responses, at extremes of age and in diverse populations. The recent Ebola virus outbreak highlighted the utility of viral vectored vaccines in facilitating a rapid response to public health emergencies. Meanwhile, technological advances in manufacturing to support scale-up of viral vectored vaccines have helped to consolidate their position as a leading approach to tackling ‘old’ and emerging infections.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Ewer (nee Russell), K., Hill, A., Dorrell, L., Lambe, T., Spencer, A., Rollier, C., & Ewer, K. (2016). Viral vectors as vaccine platforms: from immunogenicity to impact. Current Opinion in Immunology, 41, 47–54.

MLA Style

Ewer (nee Russell), K., et al. “Viral Vectors as Vaccine Platforms: from Immunogenicity to Impact.” Current Opinion in Immunology, vol. 41, Elsevier, 2016, pp. 47–54.

Chicago Style

Russell), K Ewer (nee, A Hill, L Dorrell, T Lambe, A Spencer, C Rollier, and K Ewer. 2016. “Viral Vectors as Vaccine Platforms: from Immunogenicity to Impact.” Current Opinion in Immunology 41: 47–54.
Share
Print

Access Document

Files:: current opinion Ewer et al_final_revised.pdf

(Preview, Accepted manuscript, pdf, 239.6KB, Terms of use)

Publisher copy:: 10.1016/j.coi.2016.05.014

Authors

+ Ewer (nee Russell), K More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Hill, A More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Dorrell, L More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Role:: Author

+ Lambe, T More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

+ Spencer, A More by this author

Institution:: University of Oxford
Division:: MSD
Department:: NDM
Sub department:: Jenner Institute
Role:: Author

More authors...

+ Department for International Development More from this funder

Grant:: NF-SI-0509-10233

+ Oxford NIHR Biomedical Research Centre More from this funder

+ European Research Council More from this funder

+ Wellcome Trust More from this funder

+ Medical Research Council More from this funder

Publisher:: Elsevier
Journal:: Current Opinion in Immunology More from this journal
Volume:: 41
Pages:: 47–54
Publication date:: 2016-06-07
Acceptance date:: 2016-05-24
DOI:: 10.1016/j.coi.2016.05.014
EISSN:: 1879-0372
ISSN:: 0952-7915

Pubs id:: pubs:623638
UUID:: uuid:4b66d4c6-3500-4d73-9588-0da1745e5f39
Local pid:: pubs:623638
Source identifiers:: 623638
Deposit date:: 2016-05-24

Terms of use

Copyright holder:: Elsevier
Copyright date:: 2016
Notes:: © 2017 Elsevier Ltd. All rights reserved. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: [0.1016/j.coi.2016.05.014]

Licence:: CC Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP